July 1, 2020 / 2:01 AM / 6 days ago

BRIEF-Amplia Therapeutics Announces Entitlement Offer To Fund Phase 1 Clinical Trial

July 1 (Reuters) - Amplia Therapeutics Ltd:

* ANNOUNCES UNDERWRITTEN PRO RATA ACCELERATED NON-RENOUNCEABLE ENTITLEMENT OFFER

* FULLY UNDERWRITTEN 3 FOR 5 ACCELERATED, PRO RATA NON- RENOUNCEABLE ENTITLEMENT OFFER AT $0.10 PER SHARE TO RAISE ABOUT $4.0 MILLION

* AMPLIA THERAPEUTICS LTD-PROCEEDS FROM OFFER WILL BE USED TO FUND A PHASE I CLINICAL TRIAL FOR AMP945 AND PRE- CLINICAL STUDIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below